Company research
Kuvatris Therapeutics, Inc.
CIK 1811623Updated Nov 16, 2026
SecurityPXMD · OTC · equity
Name history
PaxMedica, Inc. · through Jun 13, 2025
PXMD price & chart
Loading TradingView…
OTC:PXMD on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
25-NSE - filed by Nasdaq Stock Market LLC regarding Kuvatris Therapeutics, Inc.
15-12G filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 5.03, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 3.02, 5.01, 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
NT 10-Q filing
EFFECT filing
CORRESP filing
Financials
FY 2023 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 5,680,405Source | 2,204,318Source | 648,866Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 1,901,887Source | 444,087Source |
| Assets, CurrentUSD | 5,680,405Source | 2,204,318Source | 444,087Source |
| Prepaid Expense and Other Assets, CurrentUSD | 969,763Source | 302,431Source | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 2,295,332Source | 2,095,518Source | 10,757,729Source |
| Stockholders’ equity: | |||
| Additional Paid in CapitalUSD | 55,414,069Source | 33,847,607Source | 8,828,425Source |
| Retained Earnings (Accumulated Deficit)USD | -52,029,741Source | -33,740,016Source | -18,938,249Source |
| Stockholders' Equity Attributable to ParentUSD | 3,385,073Source | 108,800Source | -10,108,863Source |
| Liabilities and EquityUSD | 5,680,405Source | 2,204,318Source | 648,866Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 1,795,332Source | 2,095,518Source | 10,757,729Source |
| Accounts Payable, CurrentUSD | — | 721,955Source | 736,251Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 965,099Source | 1,019,071Source | 680,026Source |
| Short-term InvestmentsUSD | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -18,289,725Source | -14,801,767Source | -10,228,971Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,204,950Source | 4,418,134Source | 1,335,865Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -10,768,504Source | -6,071,183Source | -5,512,639Source |
| Cash flows from financing activities: | |||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 122,610Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 13,577,259Source | 7,528,983Source | 4,833,101Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,710,642Source | 1,901,887Source | 444,087Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | — | 500,000Source | 1,300,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -45,585Source | -161,563Source | — |
| General and Administrative ExpenseUSD | 12,230,292Source | 8,816,940Source | 4,973,245Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -18,289,725Source | -14,801,767Source | -10,228,971Source |
| Nonoperating Income (Expense)USD | -2,144,454Source | -4,197,339Source | -3,031,171Source |
| Operating ExpensesUSD | 16,145,271Source | 10,604,428Source | 7,197,800Source |
| Other Nonoperating Income (Expense)USD | -270,695Source | -64,500Source | -2,430Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | — |
| Operating Income (Loss)USD | -16,145,271Source | -10,604,428Source | -7,197,800Source |
| Other Nonoperating Income (Expense)USD | -270,695Source | -64,500Source | -2,430Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -18,290,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -18,289,725Source | -14,801,767Source | -10,228,971Source |
| Earnings Per Share, BasicUSD per share | -11Source | -1.69Source | -1.53Source |
| Earnings Per Share, DilutedUSD per share | -11Source | -1.69Source | -1.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,662,795Source | 8,741,678Source | 6,666,005Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,662,795Source | 8,741,678Source | 6,666,005Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 12,230,292Source | 8,816,940Source | 4,973,245Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -18,290,000Source | — | — |
| Interest ExpenseUSD | 9,165Source | 5,237Source | 2,805,856Source |
| Nonoperating Income (Expense)USD | -2,144,454Source | -4,197,339Source | -3,031,171Source |
| Operating ExpensesUSD | 16,145,271Source | 10,604,428Source | 7,197,800Source |
| Research and Development ExpenseUSD | 3,914,979Source | 1,787,488Source | 2,224,555Source |